Literature DB >> 25337314

111 In-pentetreotide SPECT CT Value in Follow-up of Patients with Neuro-Endocrine Tumors.

Badriya Al-Suqri1.   

Abstract

Carcinoid tumors are relatively rare and can occur in the thorax, abdomen, or pelvis. Functional imaging in the form of Indium-111 pentetreotide scanning is widely used for identification of these tumors and it exploits the fact that the vast majority of these tumors express somatostatin receptors on their cell membrane. In this report, we present a case of a 76-year-old man who was diagnosed with peritoneal carcinomatosis. The findings of the initial imaging made by planar and single photon emission computed tomography were misleading and the actual diagnosis was only made by single photon emission computed tomography/computed tomography.

Entities:  

Keywords:  111In-Pentetreotide; Neuroendocrine Tumor; OctreoScan; SPECT CT

Year:  2014        PMID: 25337314      PMCID: PMC4202224          DOI: 10.5001/omj.2014.95

Source DB:  PubMed          Journal:  Oman Med J        ISSN: 1999-768X


  7 in total

1.  Addition of octreotide functional imaging to cross-sectional computed tomography or magnetic resonance imaging for the detection of neuroendocrine tumors: added value or an anachronism?

Authors:  Diane L Reidy-Lagunes; Marc J Gollub; Leonard B Saltz
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

Review 2.  Secretin and vasoactive intestinal peptide receptors: members of a unique family of G protein-coupled receptors.

Authors:  C D Ulrich; M Holtmann; L J Miller
Journal:  Gastroenterology       Date:  1998-02       Impact factor: 22.682

Review 3.  Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.

Authors:  Dik J Kwekkeboom; Boen L Kam; Martijn van Essen; Jaap J M Teunissen; Casper H J van Eijck; Roelf Valkema; Marion de Jong; Wouter W de Herder; Eric P Krenning
Journal:  Endocr Relat Cancer       Date:  2010-01-29       Impact factor: 5.678

4.  A 5-decade analysis of 13,715 carcinoid tumors.

Authors:  Irvin M Modlin; Kevin D Lye; Mark Kidd
Journal:  Cancer       Date:  2003-02-15       Impact factor: 6.860

5.  SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours.

Authors:  Yodphat Krausz; Zohar Keidar; Igor Kogan; Einat Even-Sapir; Rachel Bar-Shalom; Ahuva Engel; Rina Rubinstein; Jonathan Sachs; Moshe Bocher; Svetlana Agranovicz; Roland Chisin; Ora Israel
Journal:  Clin Endocrinol (Oxf)       Date:  2003-11       Impact factor: 3.478

Review 6.  Scintigraphic imaging of body neuroendocrine tumors.

Authors:  Charles M Intenzo; Serge Jabbour; Henry C Lin; Jeffrey L Miller; Sung M Kim; David M Capuzzi; Edith P Mitchell
Journal:  Radiographics       Date:  2007 Sep-Oct       Impact factor: 5.333

Review 7.  Gastroenteropancreatic neuroendocrine tumours.

Authors:  Irvin M Modlin; Kjell Oberg; Daniel C Chung; Robert T Jensen; Wouter W de Herder; Rajesh V Thakker; Martyn Caplin; Gianfranco Delle Fave; Greg A Kaltsas; Eric P Krenning; Steven F Moss; Ola Nilsson; Guido Rindi; Ramon Salazar; Philippe Ruszniewski; Anders Sundin
Journal:  Lancet Oncol       Date:  2008-01       Impact factor: 41.316

  7 in total
  1 in total

Review 1.  Management of Gastrointestinal Neuroendocrine Tumors.

Authors:  Rongzhi Wang; Rui Zheng-Pywell; H Alexander Chen; James A Bibb; Herbert Chen; J Bart Rose
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2019-10-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.